Zymeworks
Bispecific antibodies and immunotherapeutic proteins for cancer and serious disease treatment
- Sector
- Biotech
- Headquarters
- MIDDLETOWN, DE
- Founded
- 2022
- Latest Form D
- $50M, Jan 2024
- Total capital
- $50M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $50M
- 1 Form D · last Jan 2024
- 34 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$50M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- ALI TEHRANIExecutive Officer, DirectorNamed in SEC Form D filings
- AMOS MICHELSONDirectorNamed in SEC Form D filings
- Carlos C. CampoyDirectorNamed in SEC Form D filings
- Chris C. AstleExecutive OfficerNamed in SEC Form D filings
- DAVID TUCKERExecutive OfficerNamed in SEC Form D filings
- Derek C. MillerDirectorNamed in SEC Form D filings
Show all 26 people
- DION MADSENDirectorNamed in SEC Form D filings
- DONALD DRAKEMANDirectorNamed in SEC Form D filings
- GORDON NGExecutive OfficerNamed in SEC Form D filings
- Haig FarrisDirectorNamed in SEC Form D filings
- Hollings C. RentonDirectorNamed in SEC Form D filings
- IAN IHNATOWYCZDirectorNamed in SEC Form D filings
- Jeffrey C. SmithExecutive OfficerNamed in SEC Form D filings
- Kelvin C. NeuDirectorNamed in SEC Form D filings
- Kenneth GalbraithDirectorNamed in SEC Form D filings
- Kenneth C. HillanDirectorNamed in SEC Form D filings
- Nancy C. DavidsonDirectorNamed in SEC Form D filings
- NEIL KLOMPASExecutive OfficerNamed in SEC Form D filings
- Nick BedfordDirectorNamed in SEC Form D filings
- NOEL HALLDirectorNamed in SEC Form D filings
- Patrick McCroskeyDirectorNamed in SEC Form D filings
- Paul C. MooreExecutive OfficerNamed in SEC Form D filings
- SHERMAINE TILLEYDirectorNamed in SEC Form D filings
- Surjit DixitExecutive OfficerNamed in SEC Form D filings
- Susan M. MahonyDirectorNamed in SEC Form D filings
- Troy M. CoxDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingCamptothecin Analogues, Conjugates And Methods Of UseUSPTOApplication 18562049
Related companies, and why
- Diffuse IncSimilar federal contract value in Biotech · null in contracts
- RIPARIAN PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- TRILOGIC PHARMA LLCSimilar federal contract value in Biotech · null in contracts
- Transition Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Spinnaker Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Noetik Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .